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1. Introduction
According to the statistical 
findings in Ukraine there are 
more than three thousands of 
children with juvenile idiopathic 
arthritis (JIA) (0.4 on 1000 of the 
children’s population), morbidity 
rate is from 2 up to 16 persons on 
10000 of children at the age to 
16 years old, from 30–50 % of the 
patients loose work abilities after 
three-five years of the disease. 
Even in case of active treatment, 
up to the 25 years of age in 30 % 
of the patients that started JIA 
in early childhood, high activity 
of the disease is saved [1, 2]. The 
activity of the disease evaluates 
the speed of the process progres-
sion, intense of its clinical man-
ifestation, effect of the carried 
treatment. Very important is to 
study development of the patho-
genesis of the JIA for the evalua-
tion of the common changes on 
the cellular level to demonstrate 
diagnostic and therapeutic abil-
ities of the disease due to esti-
mation of the mechanisms of the 
adaptation and injury of the cell 
systems with managing of the 
inflammatory response creation 
[3, 4]. At the backstage of the 
inflammatory response in case 
of JIA we can find biochemical 
and immune-chemical processes 
with regulation of exact biolog-
ical active substances, especial-
ly with cytokines, stimulating 
growth factors, nuclear compo-
nents [5]. Development of the 
inflammatory response in case 
of JIA can be due to damage of 
the apoptosis mechanisms, that 
lead to its over need activation or 
stop [6, 7]. 
Transcriptional factors, espe-
cially nuclear-kB (NF-kB) – one 
of the most important signs that 
mediate immune and inflamma-
tory response, regulate apoptosis. In the study in vitro was 
demonstrated important role of the NF-kB in forming of the 
response for drug therapy in case of reproduction of the disease 
that comes with active chronicle inflammatory reaction [8, 9]. 
That is why now seriously interested at studying of the main an-
tirheumatic drug action due to their influence at NF-kB and as 
well modulation of the signal pathways with different drugs [10].
The aim of our study was to estimate changes of the inflam-
matory response signs as well as content of NF-kB due to basic 
therapy of the JIA. 
2. Materials and methods
At our study we had checked 68 children with JIA, who 
passed their treatment at Vinnytsya regional children’s hospi-
tal within the period from 2011 
to 2014 years. Among them we 
presented 32 boys and 36 girls. 
The first group was presented 
with 32 patients that received 
methotrexate as a main drug 
for the treatment of the JIA. 
The second group was presented 
with 25 children that accept-
ed as a basic treatment strate-
gy sulfasalazine. To the third 
group we included 11 patients 
that were given lef lunomide as 
a basic treatment. Groups were 
statistically similar according to 
the age, sex and duration of the 
disease findings. The average 
duration of the disease in the 
group of the children we exam-
ined was 18.2±1.3 months. For 
the patients of the first ther-
apeutic group indications for 
the methotrexate use were: high 
signs of the process activity, 
systemic variant of the disease, 
absence of the use of other an-
tirheumatic drugs at the an-
amnesis and contraindications 
against treatment strategy. To 
the second and third features for 
the indication of such therapy 
ere: minimal or moderate activi-
ty of the disease, articular variant 
of the injury, specially mono- or 
oligoathritis contraindications 
and refuse of the parents for such 
a treatment. Methotrexate for the 
children of the first group was 
given at a middle dosage 7.5 up 
to 15 mg/m2/week, which was 
2.5 mg every 12 hours. At the 
background of methotrexate in-
dication children accepted folic 
acid at the middle dosage not 
less than 5 mg/week. Thera-
peutic dosage of the sulfasala-
zine in children with JIA was 
at the average meaning of 20 to 
50 mg/kg/day, but not more than 
2 g/week and of the lef lunomi- 
de – 20–30 mg/day. System corticoids (methylprednisolone) 
children received in a dosage not more than 0.2 mg/kg/day 
according to the prednisolone equal dose. Patients accepted as 
well non-steroid anti-inf lammatory drugs with duration not 
over 14 days in an age dosages. 
During the study we estimated general condition of the 
patients with using of the clinical and laboratory meth-
ods according to main features of the disease. As well we 
checked visual analogy scores, Childhood Health Assessment 
Questionnaire (CHAQ). Laboratory-instrumental methods 
included routine studies as well estimation of the main signs 
of inflammatory response activity – inflammatory cytokines 
in serum (Interleukin-1β and Interleukin-6), content of the 
nuclear facor-kB while using ELISA method.
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Abstract: The activity of the juvenile idiopathic arthritis eval-
uates the speed of the process progression, intense of its clini-
cal manifestation, effect of the carried treatment. 
The aim of our study was to estimate changes of the inflam-
matory response signs as well as content of NF-kB due to ba-
sic therapy of the JIA. 
Materials and methods. At our study, we had checked 68 
children with JIA, who passed their treatment at Vinnytsya 
regional children’s hospital within the period from 2011 to 
2014 years. 
Results. At the patients we studied currency of the JIA was 
characterized with articular variant of the disease, mainly in 
monoarthritis type. Laboratory activity of the inflammatory 
response characterized with increased content of the C-re-
active protein (71.2±3.7 %), inflammatory cytokines – ІL-1β 
(54.8±4.1 %) and ІL-6 (56.2±2.4 %), as well high quantity 
of the nuclear factor-kB (70.5±3.1 %). Currency of the JIA 
in children characterized with high increasing of the in-
flammatory response signs especially C-reactive protein 
(6.55(4.2;9.8)), ІL-1β (7.3(3.5;11.9)), ІL-6 (6.8(4.5;10.6)) and 
NF-kB (6.76 (4.8; 9.1)), that are in correlative connections 
with clinical signs (number of the injured and swelled joints, 
evaluation of the general condition of the child according to 
doctors and own response) of the disease activity (rxy=+0.34 
up to 0.62, p<0.01). 
Conclusion. During the managing of the basic therapy 
in children with JIA we estimated decreasing of the IL-1β 
content in patients at the background of methotrexate ad-
ministration (38.7±3.7 %), at the second group with use of 
sulfasalazine (28.5±3.5 %) and the third with leflunomide 
prescription (29.1±5.1 %), but significant decreasing of the 
ІL-6 content, that is one of the main inflammatory media-
tors and as well NF-kB was found just in group of the pa-
tients with methotrexate administration (on 36.3±3.8 % and 
32.4±2.4 % for NF-kB).
Keywords: juvenile idiopathic arthritis, children, inflammatory 
markers, treatment, NF-kB, cytokines.
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Effect of the basic therapy of the JIA provided according 
to the criteria of ACR and checked changes of both clinical 
and laboratory signs of the inf lammatory response. Criteria 
that we checked in all patients included: count of the painful 
and swell joints, as a signs that indicate clinical activity of 
the disease, degree of the functional insufficiency according 
to the CHAQ test, evaluation of the 10-points score of the 
pain in both variants (patient and doctor), as well ESR and 
CRP content. The duration of the observance at the children 
of all groups lasted for 1 year, with control studies in6 and 
12 months after the start of the basic therapy. All results were 
statistically proved with program Statistica 6.0. All data were 
expressed as mean ±SD. Estimation of differences between 
average meanings was done by coefficient «t» to Students 
method, percentage values were detected by Fishers method. 
Approvement of the differences was counted by standard 
possibility (р) – р<0.05. For difference between comparative 
values was evaluated ratio of risks. Assessment of the degree 
of inf luence of factor characteristics was evaluated by odds 
ratio for 95 %. 
3. Results of the study
At the patients we studied currency of the JIA was character-
ized with articular variant of the disease in 52 (76.4±2.6 %) cases, 
monoarthritis type was estimated in 41.2±3.4 %. Systemic 
variant of the disease was presented in 16 (23.6±3.6 %) children 
with JIA. In 29 (42.6±3.2 %) patients disease characterized 
with a high activity of the process, in 28 (41.2±3.2 %) and 
11 (16.2±2.1 %) cases we managed mild and severe signs of the 
JIA process. 
Laboratory activity of the inflammatory response char-
acterized with increased content of the C-reactive protein 
(71.2±3.7 %), inflammatory cytokines – ІL-1β (54.8±4.1 %) 
and ІL-6 (56.2±2.4 %), as well high quantity of the nuclear 
factor-kB (70.5±3.1 %). Increased level of C-reactive protein 
was found in children with JIA without any connection with 
a duration of the disease, more often in case of monoarthritis 
(61.7±3.5 %), with moderate signs of the clinical activity of 
the disease (72.05±2.8 %), functional insufficiency (80.9± 
±1.9 %) and start elements of degenerative-destructive changes 
in the joints (83.8±2.3 %). In group of the children with a du-
ration of the JIA less than 2 years more often (on 19.4±1.2 %) 
we got increased level of ІL-1β, at the same time overloading 
of the IL-6 content was more common for the patients with 
a duration of the process more than 2 years (on 26.1±1.8 %). 
We should estimate that higher meanings of the NF-kB (on 
14.0±1.1 %) we found in children with a smaller period of the 
disease and this findings depended on quantity of the injured 
and swelled joints, activity of the disease, severity of the de-
generative-destructive process in the joints (rxy=+0.34 up to 
0.62, p<0.01). With increasing of the JIA duration we found as 
well enlargement of the patients number with positive NF-kB 
test (on 16.0±1.3 %), but with small decreasing of its content. 
According to the clinical form and activity of the disease, 
speed of its progression, all our patients were divided for 3 
subgroups according to the therapeutic influence. We should 
manage that clinical currency of the disease in children of the 
first group was more severe with higher signs of the JIA activity 
(on 19.2±1.4 %), degree of the functional insufficiency (on 26.4± 
±2.1 %) and destructive-degenerative signs (on 41.3±3.5 %) in 
compare with features of the other two groups of children. Ac-
cording to the laboratory signs of the JIA in children, it was also 
more elevated in children of the first group before the adminis-
tration of the treatment (р<0.05) and based at the background 
of CRP content (10.73±0.89 mg/l), ІL-1β (7.55±0.61 pg/l), ІL-6 
(6.38±0.68 pg/l), as well NF-kB (6.42±0.56 pg/l) estimation.
We found high clinical effect of the drug therapy in 6 
positions from 8 possible in children of the first group, that 
received methotrexate as basic drug, especially it concern 
decreasing of the painful joints count (on 24.2±2.8 %), pain 
index (on 23.7±2.1 %), estimation of the general condition 
in patients version (on 16.6±1.9 %) and doctors variant (on 
12.8±1.8 %), also significantly decreased laboratory signs of 
the inflammatory response – ESR (on 35.4±4.9 %), content of 
the CRP (on 30.8±3.7 %). In children of the second group, such 
positive changes were found in 4 categories from 8 possible 
and in the third group of the children we estimated 5 points 
from 8 possible result.
Between the children of the first group clinical effect of the 
drug therapy on the level of ACR 30 was achieved in 37.5±2.7 % 
patients, in 46.8±2.4 % we got ACR 50 and in 9.3±2.9 % cases 
of JIA received ACR 70 response. At the second group of the 
patients in a term of 12 months of basic therapy currency level 
of ACR 30 was achieved in 56.0±3.4 % children, 20.0±2.8 % got 
ACR 50 and 4.1±1.2 % received ACR 70 stage of the drug therapy 
response. At the third group of the patients with JIA response 
level ACR 30 was achieved in 54.5±2.1 % cases, 27.2±1.9 % more 
demonstrated ACR 50 result. 
Effect of the inflammatory response suppression was 
demonstrated in all three groups of patients with JIA at the 
background of drug therapy use. But significantly better re-
sponse was received in the first group of the patients that 
used methotrexate and presented with decreasing of ІL-1β (on 
38.7±3.7 %) and especially ІL-6 (on 36.3±3.8 %), NF-kB (on 
32.4±2.4 %) in compare with signs before the treatment and 
overcame the same results of the patients of two other clinical 
groups. Intense suppression of the IL-6 synthesis confirm active 
pathogenic-spread action of the methotrexate, cause IL-6 is one 
of the most important inflammatory cytokines that regulates 
synthesis of both ІL-1β and CRP. And decreasing of the NF-kB 
amount prove more actual anti-inflammatory target-action of 
the methotrexate as a drug of basic strategy therapy in compare 
with other drugs. 
4. Discussion
1. Currency of the JIA in children characterized with 
high increasing of the inflammatory response signs especial-
ly C-reactive protein (6.55(4.2;9.8)), ІL-1β (7.3(3.5;11.9)), ІL-6 
(6.8(4.5;10.6)) and NF-kB (6.76 (4.8; 9.1)), that are in correlative 
connections with clinical signs (number of the injured and 
swelled joints, evaluation of the general condition of the child 
according to doctors and own response) of the disease activity 
(rxy=+0.34 up to 0.62, p< 0.01). 
2. Due to the provided treatment between all examined 
children with JIA in 32 (47.0±5.1 %) of the patients we got ACR 
30 response, 23 (33.8±4.8 %) achieved ACR 50 and in 4 (5.9± 
±1.9 %) estimated ACR 70 level. 
3. During the managing of the basic therapy in children with 
JIA we estimated decreasing of the IL-1β content in patients at 
the background of methotrexate administration (38.7±3.7 %), at 
the second group with use of sulfasalazine (28.5±3.5 %) and the 
third with leflunomide direction (29.1±5.1 %), but significant 
decreasing of the ІL-6 content, that is one of the main inflam-
matory mediators and as well NF-kB was found just in group of 
the patients with methotrexate administration (on 36.3±3.8 % 
and 32.4±2.4 % for NF-kB).
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